MabPlex Raises $71 Million for Biopharmaceutical CDMO Services
publication date: Jun 8, 2020
MabPlex International, a biologics CDMO located in Yantai, completed a $71 million Series B financing led by PE firms DT Capital Partners and Huajin Capital. Founded in 2013, MabPlex provides global CDMO services for biopharmaceuticals, including mAbs, recombinant proteins, ADCs and bispecifics. The company offers contract services that range from DNA to finished drug products. Its CHO cell line platform is designed to move candidates quickly through the development process. In early 2019, MabPlex closed a $59 million Series A financing from SDIC Venture Fund and Shenzhen Venture Capital, two state-owned investors. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.